Keros Therapeutics (NASDAQ:KROS) just reported results for the second quarter of 2024.
- Keros Therapeutics reported earnings per share of -$1.25. This was below the analyst estimate for EPS of -$1.23.
- The company reported revenue of $37,000.
Source: iQoncept / Shutterstock
Keros Therapeutics (NASDAQ:KROS) just reported results for the second quarter of 2024.
Article printed from InvestorPlace Media, https://investorplace.com/earning-results/2024/08/kros-stock-earnings-keros-therapeutics-for-q2-of-2024/.
©2025 InvestorPlace Media, LLC